About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalChina
Clinical Trials (19)
View allTotal Trials
19
As Lead Sponsor
16
As Collaborator
3
Total Enrollment
1,774
By Phase
PHASE1/PHASE2: 4PHASE2: 3PHASE1: 11PHASE3: 1
By Status
COMPLETED: 12RECRUITING: 4UNKNOWN: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline19 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06907043Collaborator
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
PHASE1/PHASE2Recruiting
130 participants
Started: Apr 30, 2025 · Completed: Dec 31, 2028
NCT06617923Collaborator
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
PHASE2Recruiting
18 participants
Started: Feb 6, 2025 · Completed: Dec 31, 2029
NCT07019194Lead Sponsor
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
PHASE1Completed
40 participants
Started: Jun 21, 2024 · Completed: Jul 15, 2024
NCT06253130Collaborator
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
70 participants
Started: Dec 11, 2023 · Completed: Dec 1, 2026
NCT05390944Lead Sponsor
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
PHASE1Completed
28 participants
Started: Jun 8, 2022 · Completed: Aug 1, 2022
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...